Incyte Corp (INCY) · Oct 29, 2026 · Earnings

Incyte earnings beat as Opzelura drives guidance raise

Beat — Revenue $1.557B vs ~$1.47B consensus; non-GAAP EPS -$3.60 vs ~$3.93 loss consensus

Incyte earnings beat revenue expectations and raised 2026 guidance, led by Opzelura and hematology/oncology growth while Vega keeps reported profit deeply negative.

Incyte is executing a post-Jakafi diversification strategy, building growth around Opzelura, newer hematology and oncology products, and a late-stage pipeline aimed at extending growth beyond the current franchise.

The quarter beat the operating expectation. Revenue reached $1.557 billion, well above the roughly $1.47 billion published consensus, with non-GAAP diluted EPS of a $3.60 loss also modestly better than the roughly $3.93 loss expected. The headline GAAP loss is much noisier because Vega created a $1.23 billion upfront R&D charge, not because the commercial business deteriorated.

FigureQ3 2026Q3 2025Consensus
Total revenue (Financial Highlights)$1.557B (+14%)$1.366B~$1.47B
Non-GAAP diluted EPS (Financial Highlights)$(3.60)$(2.26)~$(3.93)
Opzelura sales (Product sales)$254.9M (+36%)$188.0M~$227.4M
Jakafi sales (Product sales)$826.5M (+4%)$791.1M~$825.7M
Hematology and oncology sales (Company commentary)$235M (+38%)——

The more important signal is mix, not the one-quarter revenue beat. Jakafi was essentially in line with expectations, but Opzelura materially outperformed and the newer hematology/oncology portfolio grew 38%. The company explicitly framed this as continued core growth beyond Jakafi.

Guidance moved up, but only where execution is strongest. Full-year total net sales guidance rose to $5.21-$5.30 billion from $5.13-$5.26 billion, with the increases concentrated in Opzelura and hematology/oncology; Jakafi and expense guidance were unchanged. That is a cleaner positive signal than the reported EPS, because it says management sees the commercial momentum continuing rather than merely benefiting from a one-off item.

The pipeline story advanced, but remains a future value driver rather than current revenue. Incyte is moving INCA033989 toward another Phase 3 study, keeping late-stage oncology programs active, and targeting several regulatory or clinical milestones through 2027. The discontinuation of the MAESTRA-2 ovarian-cancer study shows the company is pruning weaker positioning while redirecting resources toward first-line maintenance. 〔0〕

Bottom line: This was a narrow earnings beat with a more durable positive underneath: Opzelura and newer oncology products are gaining enough traction to lift guidance, partially validating Incyte’s effort to reduce reliance on Jakafi. The Vega charge obscures near-term GAAP profitability, but it does not change the stronger commercial read-through from the quarter.

What to watch next

TRuE-HS topline data, Q4 2026

Original filing on SEC EDGAR

More Incyte Corp news

Incyte earnings beat as Opzelura drives guidance raise | INCY Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.